Table 2.

Factors associated with pathologic complete response

Univariable analysis		pCR
		Frequency	OR (95% CI)	p
Cohort	KU	57%	1.51 (1.04–2.19)	0.031
	Spanish	47%	1
Age at diagnosis	< median	57%	1.63 (1.12–2.32)	0.010
	≥ median	45%	1
Race	Non-White	58%	1.39 (0.76–2.55)	0.282
	White	50%	1
Menopausal status	Pre	56%	1.49 (1.03–2.14)	0.032
	Post	46%	1
Histological grade	1–2	43%	0.62 (0.40–0.95)	0.029
	3	54%	1
T stage	T1–2	56%	2.19 (1.42–3.36)	<0.001
	T3–4	36%	1
Lymph node status	Negative	57%	1.81 (1.25–2.61)	0.002
	Positive	43%	1
ER/PgR	ER and PgR <1%	50%	0.52 (0.20–1.27)	0.145
	ER and/or PgR 1–10%	67%	1
Germline BRCA1/2 mutation	Yes	57%	1.34 (0.78–2.30)	0.287
	No	50%	1
sTILs	≥ 30%	62%	1.96 (1.27–3.04)	0.002
	< 30%	46%	1
	Every 5% absolute increase	-	1.06 (1.02–1.09)	0.001
Multivariable analysis	pCR
	OR (95% CI)	p
Cohort (KU vs Spanish)	1.02 (0.64–1.64)	0.925
Age at diagnosis (< median vs ≥ median)	2.00 (0.96–4.16)	0.065
Menopausal status (pre vs post)	0.88 (0.42–1.83)	0.725
Histological grade (1–2 vs 3)	0.78 (0.47–1.32)	0.361
T stage (T1–2 vs T3–4)	2.08 (1.22–3.54)	0.007
Lymph node status (negative vs positive)	1.64 (1.03–2.60)	0.035
sTILs (every 5% absolute increase)	1.10 (1.02–1.18)	0.011

T stage and lymph node status are from pre-treatment clinical staging

Menopausal status is not known for n=2 patients

Histological grade is not available for n=20 patients

Lymph node status is not available for n=3 patients

Germline BRCA1/2 status is not available for n=40 patients

sTILs score is not available for n=86 patients

pCR is not known for n=2 patients

Variables that showed association with pCR at p<0.05 in univariable analysis were included in the multivariable model (variables included: cohort, age at diagnosis, menopausal status, histological grade, T stage, lymph node status, and sTILs).

Abbreviations: CI, confidence interval; ER, estrogen receptor; OR, odds ratio; pCR, pathologic complete response; PgR, progesterone receptor; sTILs, stromal tumor-infiltrating lymphocytes